HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas
Summary
The USPTO granted Patent US12589142B2 to PMCR GmbH covering pharmaceutical compositions comprising HLA-A tumor antigen peptides (4-8 peptides for MHC class I and 2+ for MHC class II) for treating breast carcinomas. The patent includes 4 claims and covers methods for preparing the composition and determining HLA peptides.
What changed
The USPTO granted Patent US12589142B2 to PMCR GmbH (inventors: Wolfgang Schönharting, Sybille Urban) for a pharmaceutical composition containing HLA tumor antigen peptides for treating breast carcinomas. The composition comprises 4-8 HLA-A peptides corresponding to MHC class I complexes and at least 2 tumor antigen peptides for MHC class II complexes, which are tumor-exclusive or tumor-associated. The patent covers treatment or prophylaxis of mammary carcinomas, including locally recurring or metastasizing forms, as well as other malignancies, leukemias, and neoplasms.
This patent grant establishes intellectual property protection for the technology; no compliance actions are required. Parties interested in licensing or developing similar peptide-based cancer immunotherapies should review this patent for freedom-to-operate considerations. The filing date was June 2, 2020, with application number 17615595.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas
Grant US12589142B2 Kind: B2 Mar 31, 2026
Assignee
PMCR GMBH
Inventors
Wolfgang Schönharting, Sybille Urban
Abstract
The present invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of mammary/breast carcinomas, in particular locally recurring or metastasizing mammary carcinomas in a patient or group of patients, who has or is suspected of having a breast carcinoma, comprising at least 4 to 8 HLA-A tumor antigen peptides corresponding to MHC class I complexes and at least 2 tumor antigen peptides corresponding to MHC class II complexes, wherein the HLA tumor antigen peptides are tumor-exclusive or tumor-associated HLA antigen peptides and are directed against at least one MHC complex including combinations thereof; a pharmaceutical composition, a kit (or parts thereof); a method for determining an HLA peptide of class I and/or II; a method for preparing a pharmaceutical composition according to the invention; and the use of a pharmaceutical composition according to the invention for the preparation of a pharmaceutical composition for the treatment of malignancies, leukemias and neoplasms.
CPC Classifications
G01N 33/57415 A61K 39/39558 A61K 2039/812 C07K 14/70539
Filing Date
2020-06-02
Application No.
17615595
Claims
4
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.